Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis.

Clin Pract Cases Emerg Med

The University of New Mexico School of Medicine, Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism, Albuquerque, New Mexico.

Published: May 2019

Empagliflozin is a sodium glucose cotransporter-2 inhibitor that inhibits renal glucose reabsorption through an insulin-independent mechanism. This class of drugs is used in the management of type 2 diabetes. A 49-year-old female with type 2 diabetes treated with empagliflozin presented to the emergency department in diabetic ketoacidosis (DKA). This case report details the series of events leading to the diagnosis of drug-induced DKA, which led to a change in the patient's diagnosis from type 2 diabetes to type 1 diabetes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497210PMC
http://dx.doi.org/10.5811/cpcem.2019.2.41795DOI Listing

Publication Analysis

Top Keywords

type diabetes
20
diabetic ketoacidosis
8
type
5
diabetes
5
empagliflozin-induced diabetic
4
ketoacidosis unmasking
4
unmasking type
4
diabetes diagnosis
4
diagnosis empagliflozin
4
empagliflozin sodium
4

Similar Publications

Background And Aims: Impaired glucose intolerance (IGT) and impaired fasting glucose (IFG) are totally different. Lifestyle modification is effective in moving from prediabetes to normoglycaemia. There is a lack of information showing the effect of lifestyle modification according to each prediabetes and assessing its effect on the degree of reversibility to normoglycaemia and on cardiometabolic markers.

View Article and Find Full Text PDF

Background: The triglyceride glucose-body mass index (TyG-BMI) is considered to be a reliable surrogate marker of insulin resistance (IR). However, limited evidence exists regarding its association with the severity of coronary artery disease (CAD), particularly in hypertensive patients with different glucose metabolic states, including those with H-type hypertension. This study aimed to investigate the relationship between TyG-BMI and CAD severity across different glucose metabolism conditions.

View Article and Find Full Text PDF

Effects of Cirsium japonicum var. maackii on avelliation of metabolic disease by improving insulin resistance.

Lab Anim Res

January 2025

Department of Laboratory Animal Medicine, College of Veterinary Medicine, Jeonbuk National University, The 1st Veterinary R&D Building Rm 301, 79 Gobong-ro, Iksan-si, Jeollabuk-do, 54596, Republic of Korea.

Background: Metabolic syndrome (MetS) refers to a group of risk factors that cause health problems, such as obesity, diabetes, dyslipidemia, and hyperglycemia. MetS is characterized by insulin resistance, which leads to abnormal insulin sensitivity. Cirsium japonicum var.

View Article and Find Full Text PDF

Critical updates on oral insulin drug delivery systems for type 2 diabetes mellitus.

J Nanobiotechnology

January 2025

School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 47500, Bandar Sunway, Selangor, Malaysia.

Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by insulin resistance, leading to elevated blood sugar levels. Exogenous insulin can counteract the diminished response to insulin and effectively controlling blood glucose levels, thereby minimizing diabetes-related complications. However, given the injectable nature of exogenous insulin, apprehensions regarding its safety and the difficulties associated with its administration have hindered its widespread and prompt utilization.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!